A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : PV / polycythemia vera

[Related PubMed/MEDLINE]
Total Number of Papers: 1251
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   PV  (>> Co-occurring Abbreviation)
Long Form:   polycythemia vera
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2014 A highly specific q-RT-PCR assay to address the relevance of the JAK2WT and JAK2V617F expression levels and control genes in Ph-negative myeloproliferative neoplasms. ASO, B2M, ET, GUSB, PLTs, PMF
2014 A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythaemia vera. ET, mPV, WHO
2014 A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea. JAK2
2014 Abnormal adhesion of red blood cells in polycythemia vera: a prothrombotic effect? MPN
2014 Analysis of the Ten-Eleven Translocation 2 (TET2) gene mutation in myeloproliferative neoplasms. ET, MPNs, TET2
2014 Angiogenic activity in the sera of patients with post-kidney transplant erythrocytosis. PTE, VEGF
2014 Anthropometric, medical history and lifestyle risk factors for myeloproliferative neoplasms in the Iowa Women's Health Study cohort. ET, MF, MPNs
2014 Antiplatelet therapy in the management of myeloproliferative neoplasms. ASA, ECLAP, ET
2014 Application of the optimized CO-rebreathing method for determination of hemoglobin mass in patients with polycythemia vera. BSA, LBM, RCV
10  2014 Assessing disease burden in patients with classic MPNs. ET, MF, MPN
11  2014 Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea. CHR, ET
12  2014 Cerebral venous thrombosis and myeloproliferative neoplasms: results from two large databases. CVT, ET, MPNs, PMF
13  2014 Chorea disclosing a polycythemia vera. JAK2
14  2014 Chronic myeloproliferative diseases. ET, PMF
15  2014 Circulating YKL-40 in myelofibrosis a potential novel biomarker of disease activity and the inflammatory state. ET, MPN
16  2014 Circulating YKL-40 in patients with essential thrombocythemia and polycythemia vera treated with the novel histone deacetylase inhibitor vorinostat. ET
17  2014 Cluster-like headache responsive to phlebotomy. ---
18  2014 Coexistence of myeloproliferative neoplasm and plasma-cell dyscrasia. ET, MGUS, MM, MPNs, PMF
19  2014 Complex karyotype in a polycythemia vera patient with a novel SETD1B/GTF2H3 fusion gene. EEC, PVSG
20  2014 Cytokine profiles in polycythemia vera and essential thrombocythemia patients: clinical implications. ET, IL, JAK2, MPNs
21  2014 Determination of accuracy of polycythemia vera diagnoses and use of the JAK2V617F test in the diagnostic scheme. EMR, MPN
22  2014 Differential sensitivity to JAK inhibitory drugs by isogenic human erythroblasts and hematopoietic progenitors generated from patient-specific induced pluripotent stem cells. iPSCs
23  2014 Distinct clustering of symptomatic burden among myeloproliferative neoplasm patients: retrospective assessment in 1470 patients. DIPSS, ET, MF, MPNs
24  2014 Dkk3 levels in patients with myeloproliferative neoplasms. Dkk-3, ET, MPN, PMF
25  2014 Elevated levels of mast cells are involved in pruritus associated with polycythemia vera in JAK2V617F transgenic mice. ---
26  2014 Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European Union. ET, MF, MPN, PMF
27  2014 Epidemiology of myeloproliferative neoplasms in the United States. ET, MF, MPNs
28  2014 Essential thrombocythemia vs. early/prefibrotic myelofibrosis: why does it matter. BM, ET, MPN, Ph-neg, PMF, WHO
29  2014 Essential thrombocythemia: Rare cause of chorea. ET, MPD
30  2014 Health resource utilization and cost associated with myeloproliferative neoplasms in a large United States health plan. ET, HRU, MF, MPN
31  2014 Hemostatic disorders in a JAK2V617F-driven mouse model of myeloproliferative neoplasm. GP, MPN
32  2014 How common are myeloproliferative neoplasms? A systematic review and meta-analysis. ET, MPNs, PMF
33  2014 How I treat polycythemia vera. ---
34  2014 Interferon alpha-2b gains high sustained response therapy for advanced essential thrombocythemia and polycythemia vera with JAK2V617F positive mutation. ET, HU, OHR
35  2014 Interferon apha 2b for treating patients with JAK2V617F positive polycythemia vera and essential thrombocytosis. ET, IFN
36  2014 It is time to change thrombosis risk assessment for PV and ET? ET
37  2014 Jak-2 positive myeloproliferative neoplasms. CEL-NOS, CML, CNL, ET, MPNs, PMF, TKIs
38  2014 JAK2V617F allele burden in patients with myeloproliferative neoplasms. ARMS-PCR, ET, MF, MPNs, RQ-PCR
39  2014 JAK2V617F allele burden is associated with thrombotic mechanisms activation in polycythemia vera and essential thrombocythemia patients. ET, PLA, TF
40  2014 JAK2V617F homozygosity drives a phenotypic switch in myeloproliferative neoplasms, but is insufficient to sustain disease. ET, UPD
41  2014 JAK2V617F monitoring in polycythemia vera and essential thrombocythemia: clinical usefulness for predicting myelofibrotic transformation and thrombotic events. ET, IRR
42  2014 JAK2V617F mutation status and allele burden in classical Ph-negative myeloproliferative neoplasms in Japan. MPNs, RCM
43  2014 JAK2V617F promotes replication fork stalling with disease-restricted impairment of the intra-S checkpoint response. ET, MPNs, PI3K, RPA
44  2014 Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. BT, CALR, CI, ET, HR, JAK2, MPL, PMF
45  2014 Loss of Stat1 decreases megakaryopoiesis and favors erythropoiesis in a JAK2-V617F-driven mouse model of MPNs. ET, IFN-gamma, JAK2, STAT1
46  2014 Masked polycythemia vera (mPV): results of an international study. mPV, mPV
47  2014 Masked polycythemia vera diagnosed according to WHO and BCSH classification. BCSH, BM, Hb, Hct, mPV, WHO
48  2014 Molecular genetic tests for JAK2V617F, Exon12_JAK2 and MPLW515K/L are highly informative in the evaluation of patients suspected to have BCR-ABL1-negative myeloproliferative neoplasms. ET, MF, MPN
49  2014 Myelofibrotic transformations of polycythemia vera and essential thrombocythemia are morphologically, biologically, and prognostically indistinguishable from primary myelofibrosis. ET, MF, PMF
50  2014 Nitric oxide scavenging by cell-free hemoglobin may be a primary factor determining hypertension in polycythemic patients. ECP, MAP
51  2014 Open-label study of oral CEP-701 (lestaurtinib) in patients with polycythaemia vera or essential thrombocythaemia with JAK2-V617F mutation. ET
52  2014 Platelet-related fibrinolysis resistance in patients suffering from PV. Impact of clot retraction and isovolemic erythrocytapheresis. CLT, CR, ECP, MCF
53  2014 Polycythemia vera disease burden: contributing factors, impact on quality of life, and emerging treatment options. JAK2
54  2014 Polycythemia vera syndrome--as a protrombothic state. CVD, PC, PS
55  2014 Polycythemia vera transforming to myelofibrosis and then biphenotype acute leukemia. BAL, MF, MPN
56  2014 Prognostication in MF: from CBC to cytogenetics to molecular markers. ET, MF, PMF
57  2014 Rethinking the diagnostic criteria of polycythemia vera. BCSH, BM, mPV, PVSG, WHO
58  2014 Survival patterns in United States (US) medicare enrollees with non-CML myeloproliferative neoplasms (MPN). ET, MF, MPN, OS, SEER, US
59  2014 The efficiency of therapeutic erythrocytapheresis compared to phlebotomy: a mathematical tool for predicting response in hereditary hemochromatosis, polycythemia vera, and secondary erythrocytosis. BV, DeltaHct, ER, HH, RBC, SE, TE
60  2014 The mutation profile of JAK2 and CALR in Chinese Han patients with Philadelphia chromosome-negative myeloproliferative neoplasms. ET, MPNs, Ph, PMF
61  2014 The orally bioavailable MDM2 antagonist RG7112 and pegylated interferon alpha 2a target JAK2V617F-positive progenitor and stem cells. HSC, MPNs, PegIFNalpha-2a, PMF
62  2014 The role of alpha-acidic glycoprotein in formation of bleeding abnormalities in patients with myeloproliferative neoplasms. AGP, ET, LDH, MPN, PMF
63  2014 The role of serum erythropoietin level and jak2 v617f allele burden in the diagnosis of polycythaemia vera. AUC, CEIA, EPO, RIA
64  2014 The thrombotic events in polycythemia vera patients may be related to increased oxidative stress. MDA, OSI, TOS
65  2014 Vertebral artery thrombosis: a rare presentation of primary polycythaemia. MPN
66  2014 WHO-histological criteria for myeloproliferative neoplasms: reproducibility, diagnostic accuracy and correlation with gene mutations and clinical outcomes. ET, MPNs, PMF
67  2014 Whole blood transcriptional profiling reveals deregulation of oxidative and antioxidative defence genes in myelofibrosis and related neoplasms. Potential implications of downregulation of nrf2 for genomic instability and disease progression. ET, HSCs, MF, ROS
68  2014 [JAK2V617F mutation and TNF-alpha expression in myeloproliferative neoplasms and their correlation]. ET, MF, MPN
69  2014 [Successful treatment with dasatinib for polycythemia vera patient emerging BCR-ABL positive clone during 13 years of treatment]. Ph, TKI
70  2013 A phase II study of Givinostat in combination with hydroxycarbamide in patients with polycythaemia vera unresponsive to hydroxycarbamide monotherapy. HC, HDACi, MPN, MTD
71  2013 Aberrant expression of signaling proteins in essential thrombocythemia. ERbeta, ET
72  2013 ADP-induced platelet aggregation and thrombin generation are increased in Essential Thrombocythemia and Polycythemia Vera. CAT, ET, TG
73  2013 Age-related differences in disease characteristics and clinical outcomes in polycythemia vera. MPN
74  2013 An unknown cause of aortic valve stenosis: polycythemia vera. Ht
75  2013 Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies. FTY720-P, PP2A
76  2013 Are MPNs vascular diseases? ET, MPNs
77  2013 Biological rationale and clinical use of interferon in the classical BCR-ABL-negative myeloproliferative neoplasms. ET, IFN, MF, MPN
78  2013 Characterization of blood donors with high haemoglobin concentration. Hb
79  2013 Chronic myeloproliferative neoplasms and risk of osteoporotic fractures; a nationwide population-based cohort study. CI, CML, CMPN, ET
80  2013 Clinical and laboratory significance of defective P2Y(12) pathway function in patients with myeloproliferative neoplasms: a pilot study. ADP, ET, MPN, PRI, VASP, WBC
81  2013 Clinics in diagnostic imaging (146). Polycythaemia vera (PV). ---
82  2013 Diagnosis according to World Health Organization determines the long-term prognosis in patients with myeloproliferative neoplasms treated with anagrelide: results of a prospective long-term follow-up. ET, MF, PMF
83  2013 Effects of imatinib mesylate in patients with polycythemia vera: results of a phase II study. WBC
84  2013 Elevated nuclear factor erythroid-2 levels promote epo-independent erythroid maturation and recapitulate the hematopoietic stem cell and common myeloid progenitor expansion observed in polycythemia vera patients. CMP, HSC, NF-E2
85  2013 Emerging drugs for polycythemia vera. HU
86  2013 Erythrocytosis in children and adolescents-classification, characterization, and consensus recommendations for the diagnostic approach. ---
87  2013 Evaluation of WHO criteria for diagnosis of polycythemia vera: a prospective analysis. EPO, RCM, WHO
88  2013 Generation of iPS cells from normal and malignant hematopoietic cells. CML, iPSCs
89  2013 Homoharringtonine is an effective therapy for patients with polycythemia vera or essential thrombocythemia who have failed or were intolerant to hydroxycarbamide or interferon-alpha therapy. ET, HHT
90  2013 Impact of JAK2 V617F mutation on hemogram variation in patients with non-reactive elevated platelet counts. AS-qPCR, CBC, ET, MPDs, MPV, P-LCR, PDW
91  2013 Inheritance of the chronic myeloproliferative neoplasms. A systematic review. AD, CML, ET, MPNs, PMF
92  2013 JAK inhibitors: pharmacology and clinical activity in chronic myeloprolipherative neoplasms. ET, JAKs, MPN, PMF
93  2013 JAK2 46/1 haplotype is associated with JAK2 V617F-positive myeloproliferative neoplasms in Japanese patients. CI, ET, JAK2, MPNs, OR, PMF
94  2013 JAK2 mutation-related disease and thrombosis. ET, MPNs
95  2013 JAK2V617F activates Lu/BCAM-mediated red cell adhesion in polycythemia vera through an EpoR-independent Rap1/Akt pathway. ---
96  2013 Laboratory detection of JAK2V617F in human myeloproliferative neoplasms. ET, PMF
97  2013 Leukocytosis in polycythemia vera and splenomegaly in essential thrombocythemia are independent risk factors for hemorrhage. ET
98  2013 Methylation of SOCS3 in Myeloproliferative Neoplasms and Secondary Erythrocytosis/Thrombocythemia. ET, MPNs, PMF
99  2013 MicroRNA deregulation in polycythemia vera and essential thrombocythemia patients. ET, miRNA
100  2013 MicroRNAs in myeloproliferative neoplasms. ET, miRNA, MPN, PMF